Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean ...
Vietnam Investment Review on MSN
Fosun Pharma Announces 2025Q3 Financial Results
Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First ...
Professor Lindsay J Hall explains how introducing probiotics into neonatal care can help combat antimicrobial resistance in ...
The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback